Lifestyle First and Lifestyle Always, Does Not Mean Lifestyle Only: Reimagining Cardiometabolic Care in the Era of GLP-1 Receptor Agonists.
This review article argues that GLP-1 receptor agonists (GLP-1 RAs) — such as semaglutide and tirzepatide — should be understood as catalysts for, rather than replacements of, lifestyle intervention in cardiometabolic care. The authors propose the guiding principle "lifestyle first and lifestyle always, but not lifestyle only," acknowledging that GLP-1 RAs have produced meaningful clinical benefits including substantial weight loss, improved glycemic control, and reduced cardiovascular and renal risk. However, the authors contend that pharmacotherapy alone cannot address the full spectrum of cardiometabolic risk drivers, including sarcopenia, physical deconditioning, poor sleep, psychological stress, and social determinants of health. The article highlights that discontinuation of GLP-1 RAs without structured lifestyle support is commonly associated with weight regain. Key lifestyle pillars emphasized include high-quality nutrition, regular physical activity (including resistance training), restorative sleep, stress management, and social connectedness. The authors advocate for integrated, interprofessional care models combining pharmacologic and lifestyle strategies, supported by systemic and policy-level change. As a narrative review, the paper does not present original data, conduct a systematic literature search, or include a meta-analysis, which limits the directness of its evidentiary contribution.
Why this grade: This is a narrative review article synthesizing existing literature and proposing a clinical framework; it does not generate original experimental or clinical trial data, precluding a higher evidence grade.
The rapid uptake of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, has transformed the management of obesity, diabetes, and cardiometabolic disease, producing substantial weight loss, improved glycemic control, and reduced cardiovascular and renal risk. This article advances a guiding principle for contemporary care: "lifestyle first and lifestyle always, but not lifestyle only." While GLP-1 RAs have reshaped clinical practice and reinforced recognition of obesity as a biologically mediated disease, pharmacotherapy alone cannot resolve the complex behavioral, physiologic, and social drivers of cardiometabolic risk. Discontinuation of GLP-1 RAs without structured lifestyle support commonly results in weight regain, and medication does not address sarcopenia, physical deconditioning, sleep, stress, psychosocial determinants, or social connection. Lifestyle behaviors, high-quality nutrition, regular physical activity including resistance training, restorative sleep, stress management, social connectedness, and a sense of purpose, constitute the physiological and behavioral foundation for durable health gains. GLP-1 RAs are therefore positioned not as substitutes for lifestyle change, but as catalysts that create metabolic and psychological conditions that are favorable to adopting and sustaining healthy behaviors. Integrated, interprofessional models that combine pharmacologic and lifestyle strategies, supported by policy and systems change, are proposed as the emerging standard for long-term cardiometabolic health.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.